Claims
- 1. A method of treating or preventing cancer in a patient comprising the steps of administering a therapeutically effective amount of a polypeptide comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 or SEQ ID NO:14 over the entire length of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 or SEQ ID NO:14 respectively, wherein the polypeptide may optionally comprise a fusion partner or an affinity tag, wherein administration of said polypeptide to said patient induces an immune response to a tumour antigen.
- 2. The method of claim 1, further comprising admixing the polypeptide with an adjuvant.
- 3. The method of claim 1, wherein the tumour antigen comprises CASB7439.
- 4. The method of claim 1, wherein the patient has or has a potential to contract a cancer comprising colorectal, breast or lung cancer.
- 5. The method of claim 1, wherein the polypeptide has at least 95% sequence identity to SEQ ID NO:2.
- 6. A method of inducing an immunoresponse to CASB7439 in a human or non-human animal comprising administering a peptide fragment of SEQ ID NO:2 to the human or non-human animal.
- 7. The method of claim 6, wherein the peptide fragment is selected from the group consisting of SEQ ID NO: 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, and 33.
- 8. The method of claim 6, wherein the peptide fragment further comprises a fusion partner.
- 9. The method of claim 6 or 8, further comprising admixing the peptide fragment with an adjuvant.
- 10. A method of manufacturing a medicament for immunotherapeutically treating a patient suffering from or susceptible to cancer comprising expressing a protein in a cell comprising a polynucleotide comprising a nucleotide sequence which has at least 70% sequence identity to the nucleotide sequence set forth in SEQ ID NO:1 over the entire length of SEQ ID NO:1.
- 11. The method according to claim 10, wherein the polynucleotide has at least 95% sequence identity to SEQ ID NO:1.
- 12. The method according to claim 10, wherein the patient is suffering from a cancer comprising colorectal, breast or lung cancer.
- 13. The method according to claim 10, wherein the polynucleotide is selected from the group consisting of
(a) a polynucleotide comprising a nucleotide sequence encoding SEQ ID NO:2; (b) the coding region of polynucleotide SEQ ID NO:1; and (c) a polynucleotide obtainable by screening an appropriate library under stingent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof, wherein said polynucleotide encodes a polypeptide having simlar properties to those fo SEQ ID NO:2.
- 14. A method of manufacturing a medicament comprising a polypeptide which has at least 70% sequence identity to the amino acid sequence set forth in SEQ ID NO:2 over the entire length of SEQ ID NO:2 for the manufacture of a medicament for immunotherapeutically treating a patient suffering from or susceptible to cancer.
- 15. The method according to claim 14, wherein the polypeptide has at least 95% sequence identity to SEQ ID NO:2.
- 16. The method according to claim 14, wherein the patient is suffering from a cancer comprising colorectal, breast or lung cancer.
- 17. An immunogenic fragment of CASB7439, wherein the immunogenic fragment is immunologically reactive with an antibody that binds to and/or a T-cell that reacts with or binds to a polypeptide comprising SEQ ID NO:2.
- 18. A pharmaceutical composition comprising the immunogenic fragment of claim 17.
- 19. A polypeptide comprising the amino acid sequence set forth in SEQ ID NO:35.
- 20. An isolated polynucleotide encoding the polypeptide of claim 19.
- 21. An expression vector comprising the polynucleotide of claim 20.
- 22. A host cell comprising the expression vector of claim 21.
Priority Claims (3)
Number |
Date |
Country |
Kind |
0004269.8 |
Feb 2000 |
GB |
|
0009905.1 |
Apr 2000 |
GB |
|
0021080.7 |
Aug 2000 |
GB |
|
CROSS REFERENCES TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part and claims benefit to U.S. application Ser. No. 10/226,872, which was filed in the United States Patent and Trademark Office on Aug. 23, 2002, which was filed as a continuation-in-part of International Application No. PCT/EP01/01779, filed on Feb. 16, 2001, which claims priority of Great Britain Patent Application No. 0004269.7, filed Feb. 23, 2000, which claims priority of Great Britain Patent Application No. 0009905.1; filed Apr. 20, 2000, which claims priority of Great Britain Patent Application No. 0021080.7, filed Aug. 25, 2000. This application also claims benefit to copending International Application Serial Nos.: PCT/EP02/05011, filed 16 May 2001 and PCT/EP02/01649, filed 21 Feb. 2001, the contents of which are incorporated herein by reference in their entirety.
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
10226872 |
Aug 2002 |
US |
Child |
10650608 |
Aug 2003 |
US |
Parent |
PCT/EP01/01779 |
Feb 2001 |
US |
Child |
10226872 |
Aug 2002 |
US |